510(k) device
Omnipod® Insulin Management System, Omnipod DASH® Insulin Management System
Insulet Corporation · Pump, Infusion, Insulin (LZG, Class II) · First FDA decision Dec 7, 2012, newest Aug 13, 2021Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
510(k) pathway
Device trials
50
Naming "Omnipod"
MAUDE reports
340,668
Brand "Omnipod", since 2015
PubMed studies
153
Mentioning "Omnipod"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Omnipod® Insulin Management System, Omnipod DASH® Insulin Management System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 8 decisions filed under this name.
K211575 · Decided Aug 13, 2021 · 84 days after receipt
Device type: Pump, Infusion, Insulin (LZG) · Hospital Medicine & Nursing
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Insulin Infusion PumpNational analysisReview closedCAG-00041NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Omnipod", any status and sponsor, newest update first.
Institut de Recherches Cliniques de MontrealAcademic, hospital or other
NCT07758647 · 33 participants (planned) · Start Nov 18, 2026 · Primary completion Sep 1, 2029
Device: Open-Source Automated Insulin Delivery (OS-AID); Commercial Automated Insulin Delivery (C-AID) · For: Type 1 Diabetes (T1D)
Sites: Montreal, Canada
49 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Omnipod", and for the whole product code for context.
This brand
340,668 reports: 302,075 malfunction, 38,063 injury, 349 death
Whole product code LZG
385,399 reports: 329,529 malfunction, 55,119 injury, 355 death
Newest reports for this brand
- Omnipod 5 Automated Insulin Delivery SystemMalfunction
3014585508-2026-79826 · Received Oct 30, 2026 · Event dated Oct 14, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow; Insufficient Device Problem Information
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding; Hyperglycemia
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2604-2026 · Started May 20, 2026 · Posted by FDA Jun 30, 2026
Reason given: External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may...
Cause as FDA categorized it: Process design · Device type: Pump, Infusion, Insulin (LZG)
6 more recall records with a free account
Published research
The most relevant PubMed records for "Omnipod"[tiab]. The summary above synthesizes these.
- Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.
Kong YW, Yuan CY, Kiburg K, et al. · J Clin Endocrinol Metab · 2024Randomized Controlled Trial, Multicenter Study
- Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.
Forlenza GP, DeSalvo DJ, Aleppo G, et al. · Diabetes Technol Ther · 2024
- Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes.
Marks BE, Meighan S, Zehra A, et al. · Diabetes Technol Ther · 2023Research Support, N.I.H., Extramural
- Impact of OMNIPOD® on the quality of life of adolescents with type 1 diabetes.
Nivet E, Lo G, Nivot-Adamiak S, et al. · Arch Pediatr · 2022Observational Study
- Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.
MacLeish SA, Hood KK, Polonsky WH, et al. · Diabetes Obes Metab · 2024Multicenter Study, Clinical Trial
- Swimming With the Omnipod 5 Automated Insulin Delivery System: Connectivity in the Water.
Hughes MS, Kingman RS, Hsu L, et al. · Diabetes Care · 2023Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- Patch Pumps for Insulin.
Ginsberg BH · J Diabetes Sci Technol · 2019Review
- Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism.
Aouchiche K, Reynaud R, Amodru V, et al. · Endocrine · 2022Review
- Patch Pumps: Periodic Insulin Delivery Patterns.
Eichenlaub M, Ziegler R, Heinemann L, et al. · J Diabetes Sci Technol · 2023
- Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes.
Berget C, Sherr JL, DeSalvo DJ, et al. · Clin Diabetes · 2022
- Canadian Real-World Outcomes of Omnipod Initiation in People with Type 1 Diabetes (COPPER study): Evidence from the LMC Diabetes Registry.
Brown RE, Vienneau T, Aronson R · Diabet Med · 2021Multicenter Study, Observational Study
- Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?
Riveline JP, Hopley C, Olivieri AV, et al. · Diabetes Metab · 2026Randomized Controlled Trial
Other devices of this type
Also filed under product code LZG.
- t:slim Insulin Delivery System, t:flex Insulin Delivery SystemTandem Diabetes Care, Inc. · 510(k) 2016
- Medtronic Minimed Paradigm Insulin PumpsMedtronic Minimed · 510(k) 2012
- Pivot Insulin Delivery SystemModular Medical, Inc. · 510(k) 2026
- Extended ReservoirMedtronic Minimed · 510(k) 2024
- Amigo Insulin PumpNipro Diabetes Systems, Inc. · 510(k) 2007
- Modular Medical MODD1 Insulin Delivery SystemModular Medical, Inc. · 510(k) 2024
- Omnipod GO Insulin Delivery DeviceInsulet Corporation · 510(k) 2023
- Omnipod DASH Insulin Management SystemInsulet Corporation · 510(k) 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.